Video

Dr. Kris on the Impact of Bevacizumab Biosimilars in Lung Cancer

Mark G. Kris, MD, discusses the impact biosimilars for bevacizumab (Avastin) could have in lung cancer.

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the impact bevacizumab (Avastin) biosimilars could have in lung cancer.

In most cases, biosimilars are viewed similarly to generic drugs, says Kris. In practice, not much attention is paid to whether patients receive a biologic or a generic drug. The same should be true of biosimilars, adds Kris.

Recently, PF-06439535 (bevacizumab-bvzr; Zirabev), a biosimilar for bevacizumab was FDA approved for patients with metastatic or recurrent non—small cell lung cancer. However, bevacizumab is not used commonly in lung cancer, says Kris, who adds that its use has likely decreased since checkpoint inhibitors were approved. Although bevacizumab biosimilars may have limited utility in lung cancer, they could have more of an impact in other diseases where the agent is used more frequently, concludes Kris.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.